Comparing the current results to its competitors, Zoetis Inc reported Revenue increase in the 2 quarter 2026 by 0.33 % year on year. The revenue growth was below Zoetis Inc 's competitors' average revenue growth of 4.91 %, achieved in the same quarter.
With modest revenue growth of 0.33 % within Overall company, Zoetis Inc failed to increase sales with the same pace, like most of company's peers within this division. << More on ZTS Market Share.
*Market share is calculated based on total revenue.
April 27, 2024
Rosen Law Firm Calls on Zoetis Inc. Investors to Participate in Securities Class Action InvestigationNew York, April 27, 2024 - Renowned global investor rights law firm, Rosen Law Firm, has recently declared an investigation to determine potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS). The firm intends to scrutinize allegations suggesting that Zoetis may have disseminated misleading business information to the investing public, which could have significant implications for shareholders and the company itself.Securities class actions are legal proceedings taken by investors against a company or its stakeholders, alleging that false or misleading statements or significant omiss...
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Phibro Animal Health Corporation Share Performance
-1.14%
Over The Past 5 Days
Phibro Animal Health Corporation
Profile
Phibro Animal Health Corporation is a leading global provider of animal health and nutrition products, catering to both livestock and companion animals. Their business model centers around producing and marketing a wide range of pharmaceuticals, vaccines, nutritional supplements, and other animal health products. They aim to serve the diverse needs of farmers, veterinarians, and pet owners, while focusing on innovation, quality, and customer satisfaction.
Idexx Laboratories Inc operates within the veterinary diagnostics industry, offering a comprehensive suite of innovative products and services tailored for veterinary practices globally. Their business model focuses on the development and manufacture of diagnostic tests, instruments, and software solutions that assist in the detection and management of animal health issues. Revenue is primarily generated through direct sales of these products to veterinarians, clinics, and laboratories, enhancing the quality of animal care through advanced diagnostic capabilities.
Sources:
Zoetis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zoetis Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
